OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. O'Connor Discusses Regorafenib Dosing in mCRC

November 30th 2018

Juan Manuel O’Connor, MD, head, Department Gastrointestinal Oncology, Department of Clinical Oncology, Institute Alexander Fleming, Buenos Aires, discusses regorafenib (Stivarga) dosing in the treatment of patients with metastatic colorectal cancer.

Dr. Triebel on Novel Immunotherapy Combination in Melanoma

November 30th 2018

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immuntep Ltd, discusses a novel immunotherapy combination in melanoma.

Implementing Quality Standards and Personalized Approaches into Oncology

November 30th 2018

Robert D. Orzechowski, MBA, chief operating officer, Lancaster Cancer Center, executive council member, NCODA, discusses the implementation of quality standards and personalized approaches into oncology.

Utility of Genome-Wide Association Studies in Pediatric Oncology

November 29th 2018

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the utility of genome-wide association studies in pediatric oncology.

Dr. Gorantla Addresses Unanswered Questions From the APHINITY Trial

November 29th 2018

Vikram C. Gorantla, MD, clinical assistant professor, UPMC Hillman Cancer Center, addresses the unanswered questions following the APHINITY trial in HER2-positive breast cancer.

Dr. Bradley on Next Steps for Research in Nonmetastatic Prostate Cancer

November 29th 2018

Deborah A. Bradley, MD, oncologist, Levine Cancer Institute, discusses next steps for research in nonmetastatic prostate cancer.

Dr. Kearns on AEs Associated With Surgery in Prostate Cancer

November 29th 2018

James Kearns, MD, assistant professor of medicine, Levine Cancer Institute, discusses adverse events associated with surgery in patients with high-risk prostate cancer.

Dr. Jagannath on the Importance of Biology in Multiple Myeloma

November 29th 2018

Sundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai Health System, discusses the importance of biology in multiple myeloma.

Dr. Kahl on Promising Research in Chronic Lymphocytic Leukemia

November 29th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses exciting data on the horizon in chronic lymphocytic lymphoma (CLL).

Dr. Komrokji Discusses the FDA Approval of Gilteritinib for FLT3+ AML

November 29th 2018

Rami S. Komrokji, MD, principal investigator, MDS Research Consortium, Aplastic Anemia and MDS International Foundation, clinical director, Hematologic Malignancies, Moffitt Cancer Center, discusses the FDA approval of gilteritinib (Xospata) for the treatment of adult patients with FLT3 mutation–positive relapsed or refractory acute myeloid leukemia.

Dr. Goy Discusses the Rituximab Biosimilar FDA Approval

November 29th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the FDA approval of the rituximab (Rituxan) biosimilar, CT-P10 (Truxima; rituximab-abbs), for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma as a single agent or in combination with chemotherapy.

Dr. Burgess on Key Data in Metastatic Castration-Sensitive Prostate Cancer

November 28th 2018

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, discusses pivotal clinical trials in metastatic castration-sensitive prostate cancer.

Dr. Hidalgo Discusses the Phase III TRYbeCA1 Trial in Pancreatic Cancer

November 28th 2018

Manuel Hidalgo, MD, PhD, professor of medicine, Harvard Medical School, chief, Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the phase III TRYbeCA1 trial in patients with advanced pancreatic adenocarcinoma.

Dr. Chi on Response to Tazemetostat in Children With INI1-Negative Tumors

November 28th 2018

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses response to tazemetostat in children with INI1-negative tumors.

Dr. Camidge on Mechanisms of Resistance to TKIs in NSCLC

November 27th 2018

D. Ross Camidge, MD, PhD, director of thoracic oncology, University of Colorado, discusses mechanisms of resistance to targeted therapies in oncogene-driven non–small cell lung cancer.

Dr. Dean Discusses Ongoing Research on Biomarkers in MCL

November 27th 2018

Robert Dean, MD, a staff physician at Cleveland Clinic, discusses ongoing research on biomarkers in mantle cell lymphoma (MCL).

Dr. Boughey on Surgical Management of Patients With Node-Positive Breast Cancer

November 27th 2018

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical management of patients with node-positive breast cancer.

Dr. Balar on Remaining Questions With Immunotherapy in Bladder Cancer

November 27th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses remaining questions with immunotherapy in bladder cancer.

Dr. O'Sullivan Discusses the Future of HER2+ Breast Cancer Treatment

November 27th 2018

Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the future for HER2-positive breast cancer treatment.

Clinical Development of Regorafenib Combinations in Pediatric Rhabdomyosarcoma

November 27th 2018

Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the clinical development of regorafenib (Stivarga) combinations in pediatric rhabdomyosarcoma.